Alzheimer, mitochondria and gender

Neuroscience and Biobehavioral Reviews

Volumn 67, Issue , 2016, Pages 89-101

  Grimm, Amandine ^a,b   Mensah Nyagan, Ayikoe Guy ^c   Eckert, Anne ^a,b  

^a UNIVERSITY OF BASEL   (Switzerland)

^b UNIVERSITY OF BASEL   (Switzerland)

^c UNIVERSITÉ DE STRASBOURG   (France)

Author keywords

Abnormally hyperphosphorylated tau protein; Aging; Alzheimer's disease; Amyloid ; Bioenergetic impairments; Gender differences; Mitochondria; Oxidative stress; Sex steroid hormones

Indexed keywords

AMYLOID BETA PROTEIN; ESTRADIOL; ESTROGEN DERIVATIVE; PROGESTERONE; PROGESTERONE DERIVATIVE; SELECTIVE ANDROGEN RECEPTOR MODULATOR; SELECTIVE ESTROGEN RECEPTOR MODULATOR; SEX HORMONE; TAU PROTEIN; TESTOSTERONE;

AGING; ALZHEIMER DISEASE; BRAIN; CORRELATION ANALYSIS; DISEASE MODEL; DISORDERS OF MITOCHONDRIAL FUNCTIONS; HORMONE SUBSTITUTION; HUMAN; MITOCHONDRION; NEUROPROTECTION; NONHUMAN; OXIDATION REDUCTION STATE; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION; REVIEW; SEX DIFFERENCE; TAUOPATHY; ANIMAL; FEMALE; MALE;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; ANIMALS; ESTRADIOL; FEMALE; GONADAL STEROID HORMONES; HUMANS; MALE; MITOCHONDRIA;

EID: 84964843658     PISSN: 01497634     EISSN: 18737528     Source Type: Journal    
DOI: 10.1016/j.neubiorev.2016.04.012     Document Type: Review

References (127)

1. Adam-Vizi, V., Chinopoulos, C., Bioenergetics and the formation of mitochondrial reactive oxygen species. Trends Pharmacol. Sci. 27 (2006), 639–645, 10.1016/j.tips.2006.10.005.
2. Alvarez-de-la-Rosa, M., Silva, I., Nilsen, J., Perez, M.M., Garcia-Segura, L.M., Avila, J., Naftolin, F., Estradiol prevents neural tau hyperphosphorylation characteristic of Alzheimer's disease. Ann. N. Y. Acad. Sci. 1052 (2005), 210–224, 10.1196/annals.1347.016.
3. Amtul, Z., Wang, L., Westaway, D., Rozmahel, R.F., Neuroprotective mechanism conferred by 17beta-estradiol on the biochemical basis of Alzheimer's disease. Neuroscience 169 (2010), 781–786, 10.1016/j.neuroscience.2010.05.031 S0306-4522(10)00751-7 [pii].
4. Anderson, G.L., et al. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. J. Am. Med. Assoc. 291 (2004), 1701–1712, 10.1001/jama.291.14.1701 (291/14/1701 [pii]).
5. Asih, P.R., et al. Testosterone replacement therapy in older male subjective memory complainers: double-blind randomized crossover placebo-controlled clinical trial of physiological assessment and safety. CNS Neurol. Disord. Drug Targets 14 (2015), 576–586.
6. Balaban, R.S., Nemoto, S., Finkel, T., Mitochondria, oxidants, and aging. Cell 120 (2005), 483–495, 10.1016/j.cell.2005.02.001.
7. Barnes, L.L., Wilson, R.S., Bienias, J.L., Schneider, J.A., Evans, D.A., Bennett, D.A., Sex differences in the clinical manifestations of Alzheimer disease pathology. Arch. Gen. Psychiatry 62 (2005), 685–691, 10.1001/archpsyc.62.6.685.
8. Barron, A.M., Pike, C.J., Sex hormones, aging, and Alzheimer's disease. Front. Biosci. (Elite Ed.) 4 (2012), 976–997.
9. Bellanti, F., Matteo, M., Rollo, T., De Rosario, F., Greco, P., Vendemiale, G., Serviddio, G., Sex hormones modulate circulating antioxidant enzymes: impact of estrogen therapy. Redox Biol. 1 (2013), 340–346, 10.1016/j.redox.2013.05.003.
10. Borras, C., Sastre, J., Garcia-Sala, D., Lloret, A., Pallardo, F.V., Vina, J., Mitochondria from females exhibit higher antioxidant gene expression and lower oxidative damage than males. Free Radic. Biol. Med. 34 (2003), 546–552 (S0891584902013564 [ii]).
11. Brinton, R.D., The healthy cell bias of estrogen action: mitochondrial bioenergetics and neurological implications. Trends Neurosci. 31 (2008), 529–537, 10.1016/j.tins.2008.07.003.
12. Brookmeyer, R., Johnson, E., Ziegler-Graham, K., Arrighi, H.M., Forecasting the global burden of Alzheimer's disease. Alzheimer's Demen.: J. Alzheimer's Assoc. 3 (2007), 186–191, 10.1016/j.jalz.2007.04.381.
13. Brunden, K.R., Trojanowski, J.Q., Lee, V.M., Advances in tau-focused drug discovery for Alzheimer's disease and related tauopathies. Nat. Rev. Drug Discov. 8 (2009), 783–793, 10.1038/nrd2959.
14. Callahan, M.J., Lipinski, W.J., Bian, F., Durham, R.A., Pack, A., Walker, L.C., Augmented senile plaque load in aged female beta-amyloid precursor protein-transgenic mice. Am. J. Pathol. 158 (2001), 1173–1177.
15. Campello, S., Scorrano, L., Mitochondrial shape changes: orchestrating cell pathophysiology. EMBO Rep. 11 (2010), 678–684, 10.1038/embor.2010.115.
16. Carroll, J.C., Rosario, E.R., Chang, L., Stanczyk, F.Z., Oddo, S., LaFerla, F.M., Pike, C.J., Progesterone and estrogen regulate Alzheimer-like neuropathology in female 3xTg-AD mice. J. Neurosci., 2007, 13357–13365, 10.1523/JNEUROSCI.2718-07.2007 (27/48/13357 [pii]).
17. Carroll, J.C., Rosario, E.R., Kreimer, S., Villamagna, A., Gentzschein, E., Stanczyk, F.Z., Pike, C.J., Sex differences in beta-amyloid accumulation in 3xTg-AD mice: role of neonatal sex steroid hormone exposure. Brain Res. 1366 (2010), 233–245, 10.1016/j.brainres.2010.10.009.
18. Carroll, J.C., Rosario, E.R., Villamagna, A., Pike, C.J., Continuous and cyclic progesterone differentially interact with estradiol in the regulation of Alzheimer-like pathology in female 3xTransgenic-Alzheimer's disease mice. Endocrinology 151 (2010), 2713–2722, 10.1210/en.2009-1487.
19. Caruso, D., et al. Age-related changes in neuroactive steroid levels in 3xTg-AD mice. Neurobiol. Aging 34 (2013), 1080–1089, 10.1016/j.neurobiolaging.2012.10.007 S0197-4580(12)00497-6 [ii].
20. Corder, E.H., Ghebremedhin, E., Taylor, M.G., Thal, D.R., Ohm, T.G., Braak, H., The biphasic relationship between regional brain senile plaque and neurofibrillary tangle distributions: modification by age, sex, and APOE polymorphism. Ann. N. Y. Acad. Sci. 1019 (2004), 24–28, 10.1196/annals.1297.005.
21. Corpechot, C., Robel, P., Axelson, M., Sjovall, J., Baulieu, E.E., Characterization and measurement of dehydroepiandrosterone sulfate in rat brain. Proc. Natl. Acad. Sci. U. S. A. 78 (1981), 4704–4707.
22. Cunningham, R.L., Singh, M., O'Bryant, S.E., Hall, J.R., Barber, R.C., Oxidative stress, testosterone, and cognition among Caucasian and Mexican-American men with and without Alzheimer's disease. J. Alzheimer's Dis. 40 (2014), 563–573, 10.3233/JAD-131994.
23. David, D.C., et al. Proteomic and functional analyses reveal a mitochondrial dysfunction in P301L tau transgenic mice. J. Biol. Chem. 280 (2005), 23802–23814, 10.1074/jbc.m500356200 (M500356200 [ii]).
24. Devi, L., Alldred, M.J., Ginsberg, S.D., Ohno, M., Sex- and brain region-specific acceleration of beta-amyloidogenesis following behavioral stress in a mouse model of Alzheimer's disease. Mol. Brain, 3, 2010, 34, 10.1186/1756-6606-3-34.
25. DuBoff, B., Gotz, J., Feany, M.B., Tau promotes neurodegeneration via DRP1 mislocalization in vivo. Neuron 75 (2012), 618–632, 10.1016/j.neuron.2012.06.026 S0896-6273(12)00588-0 [ii].
26. DuBoff, B., Feany, M., Gotz, J., Why size matters—balancing mitochondrial dynamics in Alzheimer's disease. Trends Neurosci. 36 (2013), 325–335, 10.1016/j.tins.2013.03.002.
27. Dumont, M., et al. Behavioral deficit, oxidative stress, and mitochondrial dysfunction precede tau pathology in P301S transgenic mice. FASEB J. 25 (2011), 4063–4072, 10.1096/fj.11-186650.
28. Eckert, A., et al. Oligomeric and fibrillar species of beta-amyloid (A beta 42) both impair mitochondrial function in P301L tau transgenic mice. J. Mol. Med. (Berl.) 86 (2008), 1255–1267, 10.1007/s00109-008-0391-6.
29. Eckert, A., Schulz, K.L., Rhein, V., Gotz, J., Convergence of amyloid-beta and tau pathologies on mitochondria in vivo. Mol. Neurobiol. 41 (2010), 107–114, 10.1007/s12035-010-8109-5.
30. Eckert, A., Schmitt, K., Götz, J., Mitochondrial dysfunction—the beginning of the end in Alzheimer's disease? Separate and synergistic modes of tau and amyloid-beta toxicity. Alzheimer's Res. Ther., 3, 2011, 15, 10.1186/alzrt74.
31. Eckert, A., Nisbet, R., Grimm, A., Gotz, J., March separate, strike together-role of phosphorylated TAU in mitochondrial dysfunction in Alzheimer's disease. Biochim. Biophys. Acta 1842 (2014), 1258–1266, 10.1016/j.bbadis.2013.08.013.
32. Feldman, H.A., et al. Age trends in the level of serum testosterone and other hormones in middle-aged men: longitudinal results from the Massachusetts male aging study. J. Clin. Endocrinol. Metab. 87 (2002), 589–598, 10.1210/jcem.87.2.8201.
33. Fillit, H.M., The role of hormone replacement therapy in the prevention of Alzheimer disease. Arch. Intern. Med. 162 (2002), 1934–1942.
34. Frye, C.A., Walf, A.A., Effects of progesterone administration and APPswe+PSEN1Deltae9 mutation for cognitive performance of mid-aged mice. Neurobiol. Learn. Mem. 89 (2008), 17–26, 10.1016/j.nlm.2007.09.008 S1074-7427(07)00161-X [pii].
35. Götz, J., Ittner, L.M., Animal models of Alzheimer's disease and frontotemporal dementia. Nat. Rev. Neurosci. 9 (2008), 532–544, 10.1038/nrn2420 (nrn2420 [ii]).
36. Götz, J., Chen, F., van Dorpe, J., Nitsch, R.M., Formation of neurofibrillary tangles in P301l tau transgenic mice induced by Abeta 42 fibrils. Science 293 (2001), 1491–1495, 10.1126/science.1062097 (293/5534/1491 [pii]).
37. Gallagher, J.J., Minogue, A.M., Lynch, M.A., Impaired performance of female APP/PS1 mice in the Morris water maze is coupled with increased Abeta accumulation and microglial activation. Neurodegener. Dis. 11 (2013), 33–41, 10.1159/000337458.
38. Goedert, M., Jakes, R., Mutations causing neurodegenerative tauopathies. Biochim. Biophys. Acta 1739 (2005), 240–250, 10.1016/j.bbadis.2004.08.007.
39. Goodman, Y., Bruce, A.J., Cheng, B., Mattson, M.P., Estrogens attenuate and corticosterone exacerbates excitotoxicity, oxidative injury, and amyloid beta-peptide toxicity in hippocampal neurons. J. Neurochem. 66 (1996), 1836–1844.
40. Grimm, A., Lim, Y.A., Mensah-Nyagan, A.G., Götz, J., Eckert, A., Alzheimer's disease, oestrogen and mitochondria: an ambiguous relationship. Mol. Neurobiol. 46 (2012), 151–160, 10.1007/s12035-012-8281-x.
41. Grimm, A., Schmitt, K., Lang, U.E., Mensah-Nyagan, A.G., Eckert, A., Improvement of neuronal bioenergetics by neurosteroids: implications for age-related neurodegenerative disorders. Biochim. Biophys. Acta, 2014, 10.1016/j.bbadis.2014.09.013.
42. Grimm, A., Biliouris, E.E., Lang, U.E., Götz, J., Mensah-Nyagan, A.G., Eckert, A., Sex hormone-related neurosteroids differentially rescue bioenergetic deficits induced by amyloid-beta or hyperphosphorylated tau protein. Cell. Mol. Life Sci.: CMLS 73 (2016), 201–215, 10.1007/s00018-015-1988-x.
43. Grimm, A., Friedland, K., Eckert, A., Mitochondrial dysfunction: the missing link between aging and sporadic Alzheimer's disease. Biogerontology 17 (2016), 281–296, 10.1007/s10522-015-9618-4.
44. Grueninger, F., et al. Phosphorylation of Tau at S422 is enhanced by Abeta in TauPS2APP triple transgenic mice. Neurobiol. Dis. 37 (2010), 294–306, 10.1016/j.nbd.2009.09.004 S0969-9961(09)00245-9 [ii].
45. Guglielmotto, M., et al. The up-regulation of BACE1 mediated by hypoxia and ischemic injury: role of oxidative stress and HIF1alpha. J. Neurochem. 108 (2009), 1045–1056, 10.1111/j.1471-4159.2008.05858.x.
46. Harman, D., Aging: a theory based on free radical and radiation chemistry. J. Gerontol. 11 (1956), 298–300.
47. Harper, M.E., Bevilacqua, L., Hagopian, K., Weindruch, R., Ramsey, J.J., Ageing, oxidative stress, and mitochondrial uncoupling. Acta Physiol. Scand. 182 (2004), 321–331, 10.1111/j.1365-201x.2004.01370.x.
48. Henderson, V.W., Brinton, R.D., Menopause and mitochondria: windows into estrogen effects on Alzheimer's disease risk and therapy. Prog. Brain Res. 182 (2010), 77–96, 10.1016/S0079-6123(10)82003-5.
49. Hirata-Fukae, C., et al. Females exhibit more extensive amyloid, but not tau, pathology in an Alzheimer transgenic model. Brain Res. 1216 (2008), 92–103, 10.1016/j.brainres.2008.03.079.
50. Holmes, S., Abbassi, B., Su, C., Singh, M., Cunningham, R.L., Oxidative stress defines the neuroprotective or neurotoxic properties of androgens in immortalized female rat dopaminergic neuronal cells. Endocrinology 154 (2013), 4281–4292, 10.1210/en.2013-1242.
51. Irwin, R.W., Yao, J., Hamilton, R.T., Cadenas, E., Brinton, R.D., Nilsen, J., Progesterone and estrogen regulate oxidative metabolism in brain mitochondria. Endocrinology 149 (2008), 3167–3175, 10.1210/en.2007-1227 (en.2007-1227 [ii]).
52. Ittner, L.M., Gotz, J., Amyloid-beta and tau-a toxic pas de deux in Alzheimer's disease. Nat. Rev. Neurosci. 12 (2011), 65–72, 10.1038/nrn2967.
53. Jayaraman, A., et al. 17beta-estradiol and progesterone regulate expression of beta-amyloid clearance factors in primary neuron cultures and female rat brain. Endocrinology 153 (2012), 5467–5479, 10.1210/en.2012-1464.
54. Jezek, P., Hlavata, L., Mitochondria in homeostasis of reactive oxygen species in cell, tissues, and organism. Int. J. Biochem. Cell Biol. 37 (2005), 2478–2503, 10.1016/j.biocel.2005.05.013.
55. Kalous, M., Drahota, Z., The role of mitochondria in aging. Physiol. Res. 45 (1996), 351–359.
56. Keil, U., et al. Amyloid beta-induced changes in nitric oxide production and mitochondrial activity lead to apoptosis. J. Biol. Chem. 279 (2004), 50310–50320, 10.1074/jbc.M405600200.
57. King, D.L., Arendash, G.W., Crawford, F., Sterk, T., Menendez, J., Mullan, M.J., Progressive and gender-dependent cognitive impairment in the APP(SW) transgenic mouse model for Alzheimer's disease. Behav. Brain Res. 103 (1999), 145–162.
58. Kremer, A., Maurin, H., Demedts, D., Devijver, H., Borghgraef, P., Van Leuven, F., Early improved and late defective cognition is reflected by dendritic spines in Tau.P301L mice. J. Neurosci. 31 (2011), 18036–18047, 10.1523/jneurosci.4859-11.2011.
59. LaFerla, F.M., Green, K.N., Oddo, S., Intracellular amyloid-beta in Alzheimer's disease. Nat. Rev. Neurosci. 8 (2007), 499–509, 10.1038/nrn2168.
60. Lee, H.C., Wei, Y.H., Mutation and oxidative damage of mitochondrial DNA and defective turnover of mitochondria in human aging. J. Formos. Med. Assoc.=Taiwan yi zhi 96 (1997), 770–778.
61. Leuner, K., Muller, W.E., Reichert, A.S., From mitochondrial dysfunction to amyloid beta formation: novel insights into the pathogenesis of Alzheimer's disease. Mol. Neurobiol. 46 (2012), 186–193, 10.1007/s12035-012-8307-4.
62. Leuner, K., et al. Mitochondrion-derived reactive oxygen species lead to enhanced amyloid beta formation. Antioxid. Redox Signal. 16 (2012), 1421–1433, 10.1089/ars.2011.4173.
63. Lewis, J., et al. Enhanced neurofibrillary degeneration in transgenic mice expressing mutant tau and APP. Science, 2001, 1487–1491, 10.1126/science.1058189 (293/5534/1487 [pii]).
64. Lim, Y.A., et al. Inhibition of the mitochondrial enzyme ABAD restores the amyloid-beta-mediated deregulation of estradiol. PLoS One, 6, 2011, e28887, 10.1371/journal.pone.0028887 (PONE-D-11-14664 [ii]).
65. Liu, X.A., Zhu, L.Q., Zhang, Q., Shi, H.R., Wang, S.H., Wang, Q., Wang, J.Z., Estradiol attenuates tau hyperphosphorylation induced by upregulation of protein kinase-A. Neurochem. Res. 33 (2008), 1811–1820, 10.1007/s11064-008-9638-4.
66. Lopez-Grueso, R., et al. Early, but not late onset estrogen replacement therapy prevents oxidative stress and metabolic alterations caused by ovariectomy. Antioxid. Redox Signal. 20 (2014), 236–246, 10.1089/ars.2012.5112.
67. Lu, P.H., et al. Effects of testosterone on cognition and mood in male patients with mild Alzheimer disease and healthy elderly men. Arch. Neurol. 63 (2006), 177–185, 10.1001/archneur.63.2.nct50002.
68. Mandal, P.K., Tripathi, M., Sugunan, S., Brain oxidative stress: detection and mapping of anti-oxidant marker ‘Glutathione’ in different brain regions of healthy male/female, MCI and Alzheimer patients using non-invasive magnetic resonance spectroscopy. Biochem. Biophys. Res. Commun. 417 (2012), 43–48, 10.1016/j.bbrc.2011.11.047.
69. Melcangi, R.C., Giatti, S., Garcia-Segura, L.M., Levels and actions of neuroactive steroids in the nervous system under physiological and pathological conditions: sex-specific features. Neurosci. Biobehav. Rev., 2015, 10.1016/j.neubiorev.2015.09.023.
70. Meydan, S., et al. Effects of testosterone on orchiectomy-induced oxidative damage in the rat hippocampus. J. Chem. Neuroanat. 40 (2010), 281–285, 10.1016/j.jchemneu.2010.07.006.
71. Mielke, M.M., Vemuri, P., Rocca, W.A., Clinical epidemiology of Alzheimer's disease: assessing sex and gender differences. Clin. Epidemiol. 6 (2014), 37–48, 10.2147/CLEP.S37929.
72. Nilsen, J., Brinton, R.D., Impact of progestins on estrogen-induced neuroprotection: synergy by progesterone and 19-norprogesterone and antagonism by medroxyprogesterone acetate. Endocrinology 143 (2002), 205–212.
73. Overk, C.R., Lu, P.Y., Wang, Y.T., Choi, J., Shaw, J.W., Thatcher, G.R., Mufson, E.J., Effects of aromatase inhibition versus gonadectomy on hippocampal complex amyloid pathology in triple transgenic mice. Neurobiol. Dis. 45 (2012), 479–487, 10.1016/j.nbd.2011.08.035.
74. Overk, C.R., Perez, S.E., Ma, C., Taves, M.D., Soma, K.K., Mufson, E.J., Sex steroid levels and AD-like pathology in 3xTgAD mice. J. Neuroendocrinol. 25 (2013), 131–144, 10.1111/j.1365-2826.2012.02374.x.
75. Paganini-Hill, A., Henderson, V.W., Estrogen replacement therapy and risk of Alzheimer disease. Arch. Intern. Med. 156 (1996), 2213–2217.
76. Papasozomenos, S.C., The heat shock-induced hyperphosphorylation of tau is estrogen-independent and prevented by androgens: implications for Alzheimer disease. Proc. Natl. Acad. Sci. U. S. A. 94 (1997), 6612–6617.
77. Perry, G., Nunomura, A., Hirai, K., Takeda, A., Aliev, G., Smith, M.A., Oxidative damage in Alzheimer's disease: the metabolic dimension. Int. J. Dev. Neurosci. 18 (2000), 417–421.
78. Peskind, E.R., et al. Influence of lifestyle modifications on age-related free radical injury to brain. JAMA Neurol. 71 (2014), 1150–1154, 10.1001/jamaneurol.2014.1428.
79. Pike, C.J., Carroll, J.C., Rosario, E.R., Barron, A.M., Protective actions of sex steroid hormones in Alzheimer's disease. Front. Neuroendocrinol. 30 (2009), 239–258, 10.1016/j.yfrne.2009.04.015 S0091-3022(09)00024-7 [ii].
80. Prince, M., Bryce, R., Albanese, E., Wimo, A., Ribeiro, W., Ferri, C.P., The global prevalence of dementia: a systematic review and metaanalysis. Alzheimer's Demen.: J. Alzheimer's Assoc. 9 (2013), 63–75, 10.1016/j.jalz.2012.11.007 (e62).
81. Reitz, C., Mayeux, R., Alzheimer disease: epidemiology, diagnostic criteria, risk factors and biomarkers. Biochem. Pharmacol. 88 (2014), 640–651, 10.1016/j.bcp.2013.12.024.
82. Rekkas, P.V., et al. Greater monoamine oxidase a binding in perimenopausal age as measured with carbon 11-labeled harmine positron emission tomography. JAMA Psychiatry 71 (2014), 873–879, 10.1001/jamapsychiatry.2014.250.
83. Rhein, V., Baysang, G., Rao, S., Meier, F., Bonert, A., Muller-Spahn, F., Eckert, A., Amyloid-beta leads to impaired cellular respiration, energy production and mitochondrial electron chain complex activities in human neuroblastoma cells. Cell. Mol. Neurobiol. 29 (2009), 1063–1071, 10.1007/s10571-009-9398-y.
84. Rhein, V., et al. Amyloid-beta and tau synergistically impair the oxidative phosphorylation system in triple transgenic Alzheimer's disease mice. Proc. Natl. Acad. Sci. U. S. A. 106 (2009), 20057–20062, 10.1073/pnas.0905529106 (0905529106 [pii]).
85. Rocca, W.A., Grossardt, B.R., Shuster, L.T., Oophorectomy, estrogen, and dementia: a 2014 update. Mol. Cell. Endocrinol. 389 (2014), 7–12, 10.1016/j.mce.2014.01.020.
86. Rone, M.B., Fan, J., Papadopoulos, V., Cholesterol transport in steroid biosynthesis: role of protein-protein interactions and implications in disease states. Biochim. Biophys. Acta 1791 (2009), 646–658, 10.1016/j.bbalip.2009.03.001 S1388-1981(09)00071-7 [ii].
87. Rosario, E.R., Carroll, J.C., Oddo, S., LaFerla, F.M., Pike, C.J., Androgens regulate the development of neuropathology in a triple transgenic mouse model of Alzheimer's disease. J. Neurosci. 26 (2006), 13384–13389, 10.1523/jneurosci.2514-06.2006.
88. Rosario, E.R., Carroll, J., Pike, C.J., Testosterone regulation of Alzheimer-like neuropathology in male 3xTg-AD mice involves both estrogen and androgen pathways. Brain Res. 1359 (2010), 281–290, 10.1016/j.brainres.2010.08.068.
89. Rosario, E.R., Chang, L., Head, E.H., Stanczyk, F.Z., Pike, C.J., Brain levels of sex steroid hormones in men and women during normal aging and in Alzheimer's disease. Neurobiol. Aging 32 (2011), 604–613, 10.1016/j.neurobiolaging.2009.04.008.
90. Rossouw, J.E., et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. J. Am. Med. Assoc. 288 (2002), 321–333 (joc21036 [ii]).
91. Schmitt, K., Grimm, A., Kazmierczak, A., Strosznajder, J.B., Götz, J., Eckert, A., Insights into mitochondrial dysfunction: aging, amyloid-beta, and tau-A deleterious trio. Antioxid. Redox Signal. 16 (2012), 1456–1466, 10.1089/ars.2011.4400.
92. Schuessel, K., Leutner, S., Cairns, N.J., Muller, W.E., Eckert, A., Impact of gender on upregulation of antioxidant defence mechanisms in Alzheimer's disease brain. J. Neural Transm. 111 (2004), 1167–1182, 10.1007/s00702-004-0156-5.
93. Schulz, K.L., et al. A new link to mitochondrial impairment in tauopathies. Mol. Neurobiol. 46 (2012), 205–216, 10.1007/s12035-012-8308-3.
94. Scott, E., Zhang, Q.G., Wang, R., Vadlamudi, R., Brann, D., Estrogen neuroprotection and the critical period hypothesis. Front. Neuroendocrinol. 33 (2012), 85–104, 10.1016/j.yfrne.2011.10.001.
95. Shulman, R.G., Rothman, D.L., Behar, K.L., Hyder, F., Energetic basis of brain activity: implications for neuroimaging. Trends Neurosci. 27 (2004), 489–495, 10.1016/j.tins.2004.06.005.
96. Skup, M., et al. Sex differences in grey matter atrophy patterns among AD and aMCI patients: results from ADNI. NeuroImage 56 (2011), 890–906, 10.1016/j.neuroimage.2011.02.060.
97. Song, L., et al. Analysis of tau post-translational modifications in rTg4510 mice, a model of tau pathology. Mol. Neurodegener., 10, 2015, 14, 10.1186/s13024-015-0011-1.
98. Stockburger, C., Gold, V.A., Pallas, T., Kolesova, N., Miano, D., Leuner, K., Muller, W.E., A cell model for the initial phase of sporadic Alzheimer's disease. J. Alzheimer's Dis. 42 (2014), 395–411, 10.3233/JAD-140381.
99. Swerdlow, R.H., Khan, S.M., A mitochondrial cascade hypothesis for sporadic Alzheimer's disease. Med. Hypotheses 63 (2004), 8–20, 10.1016/j.mehy.2003.12.045.
100. Swerdlow, R.H., Burns, J.M., Khan, S.M., The Alzheimer's disease mitochondrial cascade hypothesis: progress and perspectives. Biochim. Biophys. Acta 1842 (2014), 1219–1231, 10.1016/j.bbadis.2013.09.010.
101. Tamagno, E., et al. Beta-site APP cleaving enzyme up-regulation induced by 4-hydroxynonenal is mediated by stress-activated protein kinases pathways. J. Neurochem. 92 (2005), 628–636, 10.1111/j.1471-4159.2004.02895.x.
102. Tamagno, E., et al. Oxidative stress activates a positive feedback between the gamma- and beta-secretase cleavages of the beta-amyloid precursor protein. J. Neurochem. 104 (2008), 683–695, 10.1111/j.1471-4159.2007.05072.x.
103. Tamagno, E., et al. JNK and ERK1/2 pathways have a dual opposite effect on the expression of BACE1. Neurobiol. Aging 30 (2009), 1563–1573, 10.1016/j.neurobiolaging.2007.12.015.
104. Tang, M.X., et al. Effect of oestrogen during menopause on risk and age at onset of Alzheimer's disease. Lancet 348 (1996), 429–432, 10.1016/s0140-6736(96)03356-9 S0140-6736(96)03356-9 [ii].
105. Trushina, E., et al. Defects in mitochondrial dynamics and metabolomic signatures of evolving energetic stress in mouse models of familial Alzheimer's disease. PLoS One, 7, 2012, e32737, 10.1371/journal.pone.0032737.
106. Turrens, J.F., Mitochondrial formation of reactive oxygen species. J. Physiol. 552 (2003), 335–344, 10.1113/jphysiol.2003.049478.
107. Van Dam, D., De Deyn, P.P., Drug discovery in dementia: the role of rodent models. Nat. Rev. Drug Discov. 5 (2006), 956–970, 10.1038/nrd2075.
108. Vasconsuelo, A., Milanesi, L., Boland, R., Actions of 17beta-estradiol and testosterone in the mitochondria and their implications in aging. Ageing Res. Rev. 12 (2013), 907–917, 10.1016/j.arr.2013.09.001.
109. Velarde, M.C., Mitochondrial and sex steroid hormone crosstalk during aging. Longev. Healthspan, 3, 2014, 2, 10.1186/2046-2395-3-2.
110. Verdile, G., et al. Associations between gonadotropins, testosterone and beta amyloid in men at risk of Alzheimer's disease. Mol. Psychiatry 19 (2014), 69–75, 10.1038/mp.2012.147.
111. Vest, R.S., Pike, C.J., Gender, sex steroid hormones, and Alzheimer's disease. Horm. Behav. 63 (2013), 301–307, 10.1016/j.yhbeh.2012.04.006.
112. Vina, J., Borras, C., Women live longer than men: understanding molecular mechanisms offers opportunities to intervene by using estrogenic compounds. Antioxid. Redox Signal. 13 (2010), 269–278, 10.1089/ars.2009.2952.
113. Vina, J., et al. Mitochondrial oxidant signalling in Alzheimer's disease. J. Alzheimer's Dis. 11 (2007), 175–181.
114. Wallace, D.C., A mitochondrial paradigm of metabolic and degenerative diseases, aging, and cancer: a dawn for evolutionary medicine. Annu. Rev. Genet. 39 (2005), 359–407, 10.1146/annurev.genet.39.110304.095751.
115. Wang, X., Su, B., Fujioka, H., Zhu, X., Dynamin-like protein 1 reduction underlies mitochondrial morphology and distribution abnormalities in fibroblasts from sporadic Alzheimer's disease patients. Am. J. Pathol. 173 (2008), 470–482, 10.2353/ajpath.2008.071208.
116. Wang, X., et al. Amyloid-beta overproduction causes abnormal mitochondrial dynamics via differential modulation of mitochondrial fission/fusion proteins. Proc. Natl. Acad. Sci. U. S. A. 105 (2008), 19318–19323, 10.1073/pnas.0804871105.
117. Wang, X., Su, B., Lee, H.G., Li, X., Perry, G., Smith, M.A., Zhu, X., Impaired balance of mitochondrial fission and fusion in Alzheimer's disease. J. Neurosci. 29 (2009), 9090–9103, 10.1523/jneurosci.1357-09.2009.
118. Wang, J.Z., Xia, Y.Y., Grundke-Iqbal, I., Iqbal, K., Abnormal hyperphosphorylation of tau: sites, regulation, and molecular mechanism of neurofibrillary degeneration. J. Alzheimer's Dis. 33:Suppl. 1 (2013), S123–S139, 10.3233/JAD-2012-129031.
119. Yan, S.D., et al. An intracellular protein that binds amyloid-beta peptide and mediates neurotoxicity in Alzheimer's disease. Nature 389 (1997), 689–695, 10.1038/39522.
120. Yao, J., Irwin, R.W., Zhao, L., Nilsen, J., Hamilton, R.T., Brinton, R.D., Mitochondrial bioenergetic deficit precedes Alzheimer's pathology in female mouse model of Alzheimer's disease. Proc. Natl. Acad. Sci. U. S. A. 106 (2009), 14670–14675, 10.1073/pnas.0903563106 (0903563106 [pii]).
121. Yao, J., Hamilton, R.T., Cadenas, E., Brinton, R.D., Decline in mitochondrial bioenergetics and shift to ketogenic profile in brain during reproductive senescence. Biochim. Biophys. Acta 1800 (2010), 1121–1126, 10.1016/j.bbagen.2010.06.002.
122. Yao, J., Irwin, R., Chen, S., Hamilton, R., Cadenas, E., Brinton, R.D., Ovarian hormone loss induces bioenergetic deficits and mitochondrial beta-amyloid. Neurobiol. Aging 33 (2012), 1507–1521, 10.1016/j.neurobiolaging.2011.03.001 S0197-4580(11)00058-3 [ii].
123. Yin, F., Boveris, A., Cadenas, E., Mitochondrial energy metabolism and redox signaling in brain aging and neurodegeneration. Antioxid. Redox Signal. 20 (2014), 353–371, 10.1089/ars.2012.4774.
124. Yin, F., et al. The perimenopausal aging transition in the female rat brain: decline in bioenergetic systems and synaptic plasticity. Neurobiol. Aging 36 (2015), 2282–2295, 10.1016/j.neurobiolaging.2015.03.013.
125. Yue, X., et al. Brain estrogen deficiency accelerates Abeta plaque formation in an Alzheimer's disease animal model. Proc. Natl. Acad. Sci. U. S. A. 102 (2005), 19198–19203, 10.1073/pnas.0505203102.
126. Yue, M., Hanna, A., Wilson, J., Roder, H., Janus, C., Sex difference in pathology and memory decline in rTg4510 mouse model of tauopathy. Neurobiol. Aging 32 (2011), 590–603, 10.1016/j.neurobiolaging.2009.04.006.
127. Zhao, L., Mao, Z., Chen, S., Schneider, L.S., Brinton, R.D., Early intervention with an estrogen receptor beta-selective phytoestrogenic formulation prolongs survival, improves spatial recognition memory, and slows progression of amyloid pathology in a female mouse model of Alzheimer's disease. J. Alzheimer's Dis. 37 (2013), 403–419, 10.3233/JAD-122341.